American Journal of Cardiology
Volume 105, Issue 5 , Pages 664-666 , 1 March 2010

Lipid-Lowering Efficacy of Red Yeast Rice in a Population Intolerant to Statins

  • Carmelo V. Venero, MD

      Affiliations

    • University of Tennessee Medical Center, Knoxville, Tennessee
    • ,
  • Jose V. Venero, MD

      Affiliations

    • Allegheny General Hospital, Pittsburgh, Pennsylvania
    • ,
  • Dale C. Wortham, MD

      Affiliations

    • University of Tennessee Medical Center, Knoxville, Tennessee
    • ,
  • Paul D. Thompson, MD

      Affiliations

    • Henry Low Heart Center, Hartford Hospital, Hartford, Connecticut
    • University of Connecticut, Farmington, Connecticut
    • Corresponding Author InformationCorresponding author: Tel: (860) 545-2880; fax: (860) 545-2882

Received 4 August 2009 ,Revised 13 October 2009 ,Accepted 13 October 2009.

References 

  1. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403–414
  2. Heber D, Lembertas A, Lu QY, Bowerman S, Go VL. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. J Altern Complement Med. 2001;7:133–139
  3. Ma J, Li Y, Ye Q, Li J, Hua Y, Ju D, et al. Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem. 2000;48:5220–5225
  4. Goldstein MR. Effects of dietary phytosterols on cholesterol metabolism and atherosclerosis. Am J Med. 2000;109:72–73
  5. Expert Panel on DetectionEvaluationTreatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  6. Heber D, Yip I, Ashley JM, Elashoff DA, Elashoff RM, Go VL. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr. 1999;69:231–236
  7. Lin CC, Li TC, Lai MM. Efficacy and safety of Monascus purpureus went rice in subjects with hyperlipidemia. Eur J Endocrinol. 2005;153:679–686
  8. Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fonnebo V. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med. 2006;1:4
  9. Becker DJ, Gordon RY, Morris PB, Yorko J, Gordon YJ, Li M, et al. Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. Mayo Clin Proc. 2008;83:758–764
  10. Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009;150:830–839
  11. Huang CF, Li TC, Lin CC, Liu CS, Shih HC, Lai MM. Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients. Eur J Cardiovasc Prev Rehabil. 2007;14:438–440
  12. Cartin-Ceba R, Lu LB, Kolpakchi A. A “natural” threat. Am J Med. 2007;120:e3–e4
  13. Mueller PS. Symptomatic myopathy due to red yeast rice. Ann Intern Med. 2006;145:474–475
  14. Smith DJ, Olive KE. Chinese red rice-induced myopathy. South Med J. 2003;96:1265–1267
  15. Vercelli L, Mongini T, Olivero N, Rodolico C, Musumeci O, Palmucci L. Chinese red rice depletes muscle coenzyme Q10 and maintains muscle damage after discontinuation of statin treatment. J Am Geriatr Soc. 2006;54:718–720
  16. Prasad GV, Wong T, Meliton G, Bhaloo S. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation. 2002;74:1200–1201
  17. Lapi F, Gallo E, Bernasconi S, Vietri M, Menniti-Ippolito F, Raschetti R, et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian surveillance system of natural health products. Br J Clin Pharmacol. 2008;66:572–574
  18. Roselle H, Ekatan A, Tzeng J, Sapienza M, Kocher J. Symptomatic hepatitis associated with the use of herbal red yeast rice. Ann Intern Med. 2008;149:516–517

 Dr. Wortham is on the Speaker's Bureau of Novartis (East Hanover, New Jersey), Sanofi Aventis (Bridgewater, New Jersey); Dr. Thompson has received grant/research support from Merck (West Point, Pennsylvania), Pfizer (New York, New York), Astra Zeneca (Wilmington, Delaware), B. Braun (Bethlehem, Pennsylvania), GlaxoSmithKline (Research Triangle Pk, North Carolina), Roche (Nutley, New Jersey), and Genomas (Hartford, Connecticut); has been a Consultant to Astra Zeneca, Merck, Schering-Plough (Liberty Corner, New Jersey), Takeda (Deerfield, Illinois), Roche, Genomas, and Abbott (North Chicago, Illinois); has been on the Speaker's Bureau for Merck, Pfizer, Abbott, Astra Zeneca, Schering-Plough, Stock; and has been a shareholder in Zoll (Chelmsford, Massachusetts), General Electric (Fairfield, Connecticut), JA Wiley Publishing (StreetHoboken, New Jersey), Zimmer (West Center Street Warsaw, Indiana), Medtronic (Minneapolis, Minnesota), and Merck. Work performed at the Cholesterol Management Center, Henry Low Heart Center, Hartford Hospital, Hartford, Connecticut.

PII: S0002-9149(09)02588-0

doi: 10.1016/j.amjcard.2009.10.045

American Journal of Cardiology
Volume 105, Issue 5 , Pages 664-666 , 1 March 2010

Article Tools

* Image Usage & Resolution